Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BLUSFNASDAQ:DRNANASDAQ:ITCINASDAQ:TGTXNASDAQ:YMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUSFBELLUS Health$9.77$0.49▼$2.60$2.35B1.5539,610 shs3.45 million shsDRNADicerna Pharmaceuticals$38.22$38.12$19.06▼$40.14$2.99B0.81.34 million shsN/AITCIIntra-Cellular Therapies$131.87$131.87$67.68▼$131.98$14.05B0.691.52 million shsN/ATGTXTG Therapeutics$35.40-1.6%$36.98$16.65▼$46.48$5.71B1.912.91 million shs1.53 million shsYMABY-mAbs Therapeutics$4.41-2.2%$4.46$3.55▼$16.11$204.23M0.51299,267 shs113,050 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUSFBELLUS Health0.00%0.00%0.00%0.00%0.00%DRNADicerna Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ITCIIntra-Cellular Therapies0.00%0.00%0.00%-0.03%+93.95%TGTXTG Therapeutics-1.64%-5.09%+0.23%-11.10%+95.04%YMABY-mAbs Therapeutics-2.22%-14.04%-6.37%-8.12%-62.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLUSFBELLUS HealthN/AN/AN/AN/AN/AN/AN/AN/ADRNADicerna PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AITCIIntra-Cellular Therapies0.913 of 5 stars1.10.00.04.50.01.70.6TGTXTG Therapeutics3.7594 of 5 stars2.41.00.03.52.22.51.9YMABY-mAbs Therapeutics2.9188 of 5 stars4.41.00.00.01.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUSFBELLUS Health 0.00N/AN/AN/ADRNADicerna Pharmaceuticals 0.00N/AN/AN/AITCIIntra-Cellular Therapies 2.17Hold$109.70-16.81% DownsideTGTXTG Therapeutics 2.80Moderate Buy$40.8015.25% UpsideYMABY-mAbs Therapeutics 2.82Moderate Buy$15.60253.74% UpsideCurrent Analyst Ratings BreakdownLatest YMAB, TGTX, DRNA, BLUSF, and ITCI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025YMABY-mAbs TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$20.00 ➝ $15.005/28/2025YMABY-mAbs TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$21.00 ➝ $18.005/19/2025YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $11.005/14/2025YMABY-mAbs TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $14.005/14/2025YMABY-mAbs TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.004/22/2025YMABY-mAbs TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeNeutral ➝ Underperform$3.004/2/2025ITCIIntra-Cellular TherapiesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$132.00 ➝ $132.00(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUSFBELLUS Health$30K0.00N/AN/A$0.25 per share0.00DRNADicerna Pharmaceuticals$164.31M18.17N/AN/A$1.84 per share20.77ITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44TGTXTG Therapeutics$329M17.08$0.12 per share300.01$1.43 per share24.76YMABY-mAbs Therapeutics$87.68M2.28N/AN/A$2.05 per share2.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUSFBELLUS Health-$7.01M-$0.10N/AN/AN/A-49,910.34%-48.37%-45.25%N/ADRNADicerna Pharmaceuticals-$112.75M-$1.63N/AN/AN/A-64.53%-103.08%-16.58%N/AITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/ATGTXTG Therapeutics$23.38M$0.24147.5035.40N/A10.13%18.88%7.05%8/5/2025 (Estimated)YMABY-mAbs Therapeutics-$29.67M-$0.64N/AN/AN/A-31.84%-30.59%-22.70%8/11/2025 (Estimated)Latest YMAB, TGTX, DRNA, BLUSF, and ITCI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025YMABY-mAbs Therapeutics-$0.22-$0.12+$0.10-$0.12$19.97 million$20.90 million5/7/2025Q1 2025TGTXTG Therapeutics$0.19$0.03-$0.16$0.03$117.07 million$120.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLUSFBELLUS HealthN/AN/AN/AN/AN/ADRNADicerna PharmaceuticalsN/AN/AN/AN/AN/AITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/AYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUSFBELLUS HealthN/A13.8713.87DRNADicerna PharmaceuticalsN/A2.462.46ITCIIntra-Cellular TherapiesN/A7.667.51TGTXTG Therapeutics1.034.023.04YMABY-mAbs TherapeuticsN/A4.774.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUSFBELLUS HealthN/ADRNADicerna Pharmaceuticals78.91%ITCIIntra-Cellular Therapies92.33%TGTXTG Therapeutics58.58%YMABY-mAbs Therapeutics70.85%Insider OwnershipCompanyInsider OwnershipBLUSFBELLUS Health24.17%DRNADicerna Pharmaceuticals10.20%ITCIIntra-Cellular Therapies2.60%TGTXTG Therapeutics10.64%YMABY-mAbs Therapeutics19.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLUSFBELLUS Health10159.12 millionN/ANot OptionableDRNADicerna Pharmaceuticals30278.13 million70.16 millionOptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableTGTXTG Therapeutics290158.76 million141.86 millionOptionableYMABY-mAbs Therapeutics15045.28 million36.36 millionOptionableYMAB, TGTX, DRNA, BLUSF, and ITCI HeadlinesRecent News About These CompaniesYMAB Y-mAbs Therapeutics, Inc. - Seeking AlphaJune 28, 2025 | seekingalpha.comY mAbs Therapeutics News (YMAB) - Investing.comJune 26, 2025 | investing.comWe're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn RateJune 11, 2025 | finance.yahoo.comWesbanco Bank Inc. Acquires Shares of 55,000 Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)June 11, 2025 | marketbeat.comCantor Fitzgerald Comments on YMAB FY2026 EarningsJune 10, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of "Moderate Buy" from AnalystsJune 9, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Bank of America Corp DEJune 8, 2025 | marketbeat.comY-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded PipelineMay 28, 2025 | globenewswire.comY-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025May 26, 2025 | insidermonkey.comY-mAbs Therapeutics Presents GD2-SADA Data at Advances in Neuroblastoma Research MeetingMay 26, 2025 | quiverquant.comQY-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research MeetingMay 26, 2025 | globenewswire.comY-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdlesMay 24, 2025 | investing.comTruist Financial Sticks to Its Buy Rating for Y-Mabs Therapeutics (YMAB)May 16, 2025 | theglobeandmail.comY-mAbs Therapeutics Inc (YMAB) Q1 2025 Earnings Call Highlights: Navigating Growth and ChallengesMay 14, 2025 | finance.yahoo.comY-mAbs Therapeutics, Inc.: Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate DevelopmentsMay 13, 2025 | finanznachrichten.deY-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comY-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue EstimatesMay 13, 2025 | zacks.comY-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025May 13, 2025 | globenewswire.comY-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate DevelopmentsMay 13, 2025 | globenewswire.comY-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)May 7, 2025 | globenewswire.comWhy Y-mAbs Therapeutics, Inc.’s (YMAB) Stock Is Down 5.65%May 6, 2025 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeYMAB, TGTX, DRNA, BLUSF, and ITCI Company DescriptionsBELLUS Health OTCMKTS:BLUSFBELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.Dicerna Pharmaceuticals NASDAQ:DRNADicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.Intra-Cellular Therapies NASDAQ:ITCI$131.87 0.00 (0.00%) As of 04/2/2025Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.TG Therapeutics NASDAQ:TGTX$35.40 -0.59 (-1.64%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$35.45 +0.05 (+0.14%) As of 07/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.Y-mAbs Therapeutics NASDAQ:YMAB$4.41 -0.10 (-2.22%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$4.42 +0.00 (+0.11%) As of 07/1/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
